Inhibiting colitis and colorectal tumor through DCIR inhibition (IMAGE)
Caption
A new study by researchers from Japan and China has revealed that inhibiting DCIR, a C-type lectin receptor protein responsible for maintaining homeostasis in the immune and bone systems, reduces the severity of DSS colitis symptoms and suppresses colorectal tumor growth. These findings could pave the way for therapeutic strategies targeting DCIR for treating colorectal tumors.
Credit
Yoichiro Iwakura from Tokyo University of Science, Japan
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND